Hirakawa Hidetada, Takita Ayako, Uchida Motoyuki, Kaneko Yuka, Kakishima Yuto, Tanimoto Koichi, Kamitani Wataru, Tomita Haruyoshi
Department of Bacteriology, Graduate School of Medicine, Gunma University, Maebashi, Gunma 371-8511, Japan.
R&D Strategy & Planning Department, Kureha Corporation, 16 Ochiai, Iwaki, Fukushima 974-8686, Japan.
Antibiotics (Basel). 2021 Apr 13;10(4):434. doi: 10.3390/antibiotics10040434.
AST-120 (Kremezin) is used to treat progressive chronic kidney disease by adsorbing uremic toxin precursors produced by the gut microbiota, such as indole and phenols. Previously, we found that AST-120 decreased drug tolerance and virulence in by adsorbing indole. Here, we show that AST-120 adsorbs phenazine compounds, such as pyocyanin, produced by including multidrug-resistant strains, and suppresses pyocyanin-associated toxicity in A-549 (alveolar adenocarcinoma) and Caco-2 (colon adenocarcinoma) cells. Addition of fosfomycin, colistin and amikacin, which are often used to treat , inhibited the bacterial growth, regardless of the presence or absence of AST-120. These results suggest a further benefit of AST-120 that supports anti-Pseudomonas chemotherapy in addition to that of and propose a novel method to treat infection.
AST - 120(可益能)通过吸附肠道微生物群产生的尿毒症毒素前体(如吲哚和酚类)来治疗进行性慢性肾病。此前,我们发现AST - 120通过吸附吲哚降低了细菌的耐药性和毒力。在此,我们表明AST - 120可吸附包括多重耐药菌株在内的铜绿假单胞菌产生的吩嗪化合物(如绿脓菌素),并抑制A - 549(肺泡腺癌)和Caco - 2(结肠腺癌)细胞中与绿脓菌素相关的毒性。通常用于治疗铜绿假单胞菌感染的磷霉素、黏菌素和阿米卡星的添加,无论是否存在AST - 120,均能抑制细菌生长。这些结果表明,AST - 120除了具有吸附尿毒症毒素的益处外,还支持抗铜绿假单胞菌化疗,并提出了一种治疗铜绿假单胞菌感染的新方法。